Abstract: A therapeutic composition includes a salicylate administering concert with at least one salicylate excretion compound of a glycine salicylate conjugate and a gluconoride salicylate conjugate. A therapeutic composition is provided that has an extended excretion half-life for a salicylate that includes the administration of the salicylate in concert with an enzymatic substrate competitor. The enzymatic substrate competitor being competitive with salicylate or gluconoride. Salicylate enzymatic substrate competitors include benzoate or other aromatic derivatives, while gluconoride enzymatic substrate competitors include an active phenolic unit. A process for treating a human or non-human subject includes administering to a subject a therapeutically effective amount of a salicylate and a salicylate pharmacokinetics modifier of glycine salicylate conjugate, gluconoride salicylate conjugate, benzoate, an aromatic derivative and an active phenolic unit, along with a pharmaceutically acceptable carrier.